American Association for Cancer Research

AACR in the News

AACR Opens Call for Ideas for a New Stand Up To Cancer-St. Baldrick's Foundation Pediatric Cancer Dream Team


October 2, 2012

Bookmark and Share

PHILADELPHIA — Stand Up To Cancer (SU2C) and the St. Baldrick’s Foundation, along with the American Association for Cancer Research (AACR), call upon the cancer research community to submit applications for a new pediatric cancer Dream Team.

The SU2C-St. Baldrick’s Pediatric Dream Team Translational Cancer Research Grant will provide funding of up to $14.5 million over a four-year period for translational pediatric cancer research projects poised to deliver near-term patient benefit through investigation by a multidisciplinary, multi-institutional, synergistic Dream Team of expert investigators.

This is the first Stand Up To Cancer Dream Team focused solely on pediatric cancer research since SU2C was launched in 2008.

The pairing of Stand Up To Cancer and the St. Baldrick’s Foundation brings together two of the world’s leading cancer research fundraising groups in a unified mission to accelerate the development of new methods to treat pediatric cancers. The AACR has played an integral role as the scientific partner of Stand Up To Cancer by providing scientific leadership, expert peer review and grants administration. The AACR is responsible for administering these grants and provides ongoing scientific oversight to ensure that progress is being made.

A SU2C-St. Baldrick’s Joint Scientific Advisory Committee (JSAC) will conduct a unique, interactive, rapid and rigorous evaluation of the applications via a multi-step scientific review process.

The JSAC is comprised of highly accomplished senior laboratory researchers and physician-scientists, as well as advocates. The committee itself is chaired by Nobel Laureate Phillip A. Sharp, Ph.D., institute professor at the David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology, and will be co-chaired by researchers representing SU2C and the St. Baldrick’s Foundation.

Deadline: Letters of Intent for the SU2C-St. Baldrick’s Pediatric Dream Team Translational Cancer Research Grant must be submitted by 12 p.m. (noon) ET on Nov. 1, 2012. Interested applicants should submit Letters of Intent detailing their best ideas for pediatric cancer research using proposalCENTRAL at: https://proposalcentral.altum.com.
The pediatric cancer Dream Team is slated to be announced in April 2013.

  • For general information on eligibility criteria, the application process and other details about the SU2C-St. Baldrick’s Pediatric Dream Team Translational Cancer Research Grant, please visit: www.aacr.org/su2cfunding.
  • Inquiries may also be directed to the SU2C Grants Office at: (267) 765-1049 or su2c@aacr.org.
# # #

Media Contacts:
Marc McCarthy                    
St. Baldrick’s Foundation            
(626) 792-8247 x40                
marc@stbaldricks.org                

Adam Pockriss
Stand Up To Cancer
(212) 843-8286
apockriss@rubenstein.com

Tara Yates
American Association for Cancer Research
(215) 446-7110
tara.yates@aacr.org

About St. Baldrick’s Foundation
The St. Baldrick’s Foundation is a volunteer-driven charity committed to funding the most promising research to find cures for childhood cancers and give survivors long and healthy lives. Since 2005, St. Baldrick’s has awarded more than $100 million to support lifesaving research, making the Foundation the largest private funder of childhood cancer research grants. St. Baldrick’s funds are granted to some of the most brilliant childhood cancer research experts in the world and to younger professionals who will be the experts of tomorrow. Funds awarded also enable hundreds of local institutions to participate in national pediatric cancer clinical trials. For more information about the St. Baldrick’s Foundation please call 1-888-899-BALD or visit www.StBaldricks.org.

About Stand Up To Cancer
Stand Up To Cancer (SU2C) — a program of the Entertainment Industry Foundation (EIF), a 501(c)3 charitable organization — raises funds to hasten the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives. In the fall of 2007, a group of women whose lives have all been affected by cancer in profound ways began working together to marshal the resources of the media and entertainment industries in the fight against this disease.

Members of the SU2C Executive Leadership Council (ELC) include Talk Show Host, Journalist and well-known Cancer Advocate Katie Couric; Sherry Lansing, Chairperson of the Entertainment Industry Foundation’s Board of Directors and founder of the Sherry Lansing Foundation; EIF President and CEO Lisa Paulsen; EIF Senior Vice President Kathleen Lobb; Rusty Robertson and Sue Schwartz of the Robertson Schwartz Agency; Pamela Oas Williams, President of Laura Ziskin Productions and Executive Producer of Stand Up To Cancer’s In-House Production Team, and Nonprofit Executive Ellen Ziffren. All of the ELC members were co-producers of the 2012 televised special. The late Laura Ziskin, executive producer of both the Sept. 5, 2008 and Sept. 10, 2010 broadcasts, was also a member of the ELC. SU2C was formally launched on May 27, 2008. Sung Poblete, Ph.D., R.N., has served as SU2C’s president and CEO since 2011.

SU2C’s “Dream Team” approach to funding translational cancer research enables scientists from different disciplines at research centers across the country and internationally to collaborate on projects geared toward getting new, less toxic treatments to patients as quickly as possible. Monies also support innovative cancer research projects that are often deemed “too risky” by conventional funding sources. Sixty-five institutions are currently involved. As SU2C’s scientific collaborator, the American Association for Cancer Research, led by a prestigious SU2C Scientific Advisory Committee, provides scientific oversight, expert review of the research projects and grants administration. For more information, visit standup2cancer.org.

About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.